Medline Inc. (MDLN) intrinsic value & 10-year financials
Medline Inc. (MDLN) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 4 fiscal years revenue grew 10.6% a year to $28.4B, with an average return on invested capital of 9.4%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $35.96
- Market cap
- $29.1B
- Revenue (FY2025)
- $28.4B
- Revenue growth (4-yr CAGR)
- 10.6%
- ROIC (10-yr avg)
- 9.4%
- Free cash flow (FY2025)
- $1.3B
MDLN 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $28.4B | $1.2B | -$0.01 | $1.3B | 7.8% | 9.4% |
| FY2024 | $25.5B | $1.2B | — | $1.4B | 8.4% | — |
| FY2023 | $23.2B | $234.0M | — | $1.4B | 5.4% | — |
| FY2022 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Medline Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Medline Inc. returns on capital have been average, hovering around 9.4% ROIC over the decade.
Medline Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Medline Inc. is modeled at 10.6% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-0.26 per share.